Southbreeze: For you to dismiss dilution as a legitimate

New Post Public Reply Private Reply Replies (5) Message Board
Daveludlow SouthBreeze #6207
Southbreeze: For you to dismiss dilution as a legitimate concern for AMBS shareholders is incredibly naive! We are a small bio-med penny stock. Did you not know that dilution was one of the major dangers facing the shareholders of such stocks? To think AMBS is shielded from this danger is plain ignorant.

The same things Gerald is saying about why we need this second billion shares (Hostile take overs, acquisitions, spin offs, etc) are all things he said when he raised the authorized shares to one billion in 2013. What percentage of the dilution we've experienced over the past 18 months has gone for those issues and what percentage has gone to simply fund the company? That's a legitimate point to be considered.

Some say dilution is just a fact of life for small penny stock biomeds. Yes, "some" dilution is. It is the responsibility of shareholders to keep a watchful eye on management and question them when dilution flags are appearing. Some here on this board have drunk so much AMBS Kool Aid that to question management is akin to blasphemy! Honestly, this mb has become almost like a religious cult to the point where if someone dares to question the company.....the board pounces on them.

I pounce on obvious bashers all the time! So what goes around comes around. I get it. But I'm no obvious basher, I'm an obvious long. For others on the mb not to realize that and think I am "soft bashing" shows they are severely lacking in perception and critical thinking.

Management doesn't worry about dilution in the same way shareholders do. My family's 1.1 million shares represents hard earned money. Management has millions of shares given to them as part of their compensation package. When someone owns 6 million shares instead of 500,000 shares, dilution doesn't really matter as much because no matter how much dilution there is....as long as the stock does reasonable well, they will still be worth multiple millions! Not so for the little guy.

I am a long. I believe in AMBS science. I am first about LymPro revenue, second about MANF's endless potential down the road, and third....I believe everything else is gravy. (Eltoprazine & Phenoguard). I'm no biotech expert, (and neither is the guy with that alias) but I've been around the small bio med business long enough to know 3 things:

1) Biotech Management has to engage in "sausage" making. (What goes on behind the scenes is not something shareholders would be happy about if they fully knew) This is just reality. Most small bio-techs don't realize their dreams, neither do most new drugs.

2) Biotechs Dilute to Keep their Dreams Alive. They have to. Big Pharma don't treat them kindly or try to help them out.....BP hopes AMBS fails.

3) Some Small Biotechs Make it Incredibly Big!! But those who do are a relatively small percentage of the total.

These 3 things I've learned have made me question every stock I'm in. I don't view management as though they were God's representatives. To be safe, I view them as God's competitor's representatives. This is not personal, it's just business. IMHO, when shareholders stop questioning management because they are in love with the dream management has created about how how rich they'll all become....that is when really bad things can happen to shareholders.

This mb would be better served if it were more tolerant of questions about what management is doing rather than 95% of all posts being about how wonderful MANF is!!!!!!! We get it. MANF is wonderful. But what if we only posted that 50% of the time, and the other 50% we discussed legitimate concerns? Not concerns raised by obvious bashers and flippers like Solantey and such, but coming from legitimate longs.

I think Gerald and management need to hear from shareholders about their real concerns. The Shareholder Meeting would be a good place for voicing some of those honest concerns. Unlike Warp, I thought the gentleman who pressed Gerald on those 5 questions during the CC was right on!! Warp writes off discussion about concerns as anxious "hand wringing" and the cause of "sleepless nights" that only the poor engage in, who really shouldn't be invested in this type of stock in the first place. I thought the gentleman asking the questions on the CC was respectful, but earnest. Sending Gerald messages all the time about how much we all admire him is not what he really needs. He's the CEO managing our investment. He needs to hear from us. We need to discuss issues seriously...not just dream of how rich we'll be.

Gerald needs to know that his credibility is on the line over the way he has mismanaged expectations. At the Jan. Conference in SF he said we wouldn't be pursuing a LymPro partner in the immediate future because of the "codes" they found that had increased the Net Present Value of LymPro multiple times! We haven't really heard about those "codes" since and we are trading at less than we were in January when he announced it!

Several months after January Gerald stated they had "identified" a LymPro Partner which would be announced at the end of summer. I think most of us anticipated it would be a "classic partner" with up front money. So when he tweeted that Friday afternoon about how excited he was over the news the next week....it was a real shock that Monday morning when we got a "master service agreement" with ICON rather than a "Classic Partnership" with J&J with 40 million dollars up front!!! These two examples I've mentioned, along with the data debacle during the July Conferences are examples of how Gerald has not managed expectations or executed flawlessly. (Not that I want him replaced)

At the beginning of the year his goal was to up list in Q2 of 2014. Now we are hearing Q1 2015. People have criticized me for worrying too much about the short term pps. They think I need reminding that this is a long term investment. I get it. All I am saying is that until more shareholder value is created....management should no leverage our shares with a billion additional shares! There's no good reason for doing a billion shares now, not when we're trading at .10 cents in mid September.

To not discuss these concerns on this mb and not raise them with management, but simply let them double the AS shares without even a peep from us.....is nothing more than Kool Aid drinking insecurity!!

I hope as participants in this mb we can mature into something more. We are the owners of AMBS and we need to intelligently raise our voice to management on an ongoing basis, so that together we can realize the incredible potential AMBS has!

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 9

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading

Top 5 Most Recently Viewed Articles

A Comprehensive Look at Apple's Competitive Position in Tech

Updated Category News Views 313

Understanding Apple's Competitive Landscape In today's dynamic business environment, a deep-dive analysis of top companies is essential for investors and industry insiders. This examination will focus on Apple (AAPL), alongside its chief rivals in the Technology Hardware, Storage & Peripherals sector. By analyzing crucial financial indicators, market positioning, and...

Continue Reading
Cegedim Shares Insights on Latest Liquidity Contract Performance

Updated Category News Views 135

Overview of Cegedim's Liquidity Contract Statement This article covers the latest updates on Cegedim’s liquidity contract performance, highlighting significant figures and trends that reflect the company's financial health. Cegedim has established a robust liquidity contract with Rothschild Martin Maurel, aimed at promoting transparency and liquidity in its shares. Key...

Continue Reading
Silexion Therapeutics Advances SIL204 for Pancreatic Cancer

Updated Category News Views 136

Silexion Therapeutics Moves Forward with SIL204 Silexion Therapeutics Corp. (NASDAQ: SLXN) is celebrating a significant milestone with the completion of crucial toxicology studies for its innovative RNA silencing therapy, SIL204. This groundbreaking therapy, designed to target mutated KRAS oncogenes, has shown no signs of systemic organ toxicity, reinforcing the...

Continue Reading
Emerson Partners with LifeSight for Enhanced Pension Solutions

Updated Category News Views 178

Emerson Partners with LifeSight for Pension Solutions LifeSight, WTW’s UK defined contribution (DC) master trust, has stepped into a significant role by becoming the full master trust provider for Emerson, the advanced electronics powerhouse. This partnership aims to cover all active, deferred, and drawdown members effectively, ensuring they are well-accommodated in...

Continue Reading
Howard Marks Joins Alliance for Decision Education Board

Updated Category News Views 227

Exciting News from the Alliance for Decision Education The Alliance for Decision Education is thrilled to announce an important addition to its Board of Directors. Howard Marks, a leader in investment management and a well-respected voice in decision-making, has agreed to join the board. As the co-chairman and co-founder of Oaktree Capital Management, Marks brings with...

Continue Reading